TimesSquare Capital Management LLC Has $91.25 Million Stock Position in argenex SE $ARGX

TimesSquare Capital Management LLC lowered its holdings in argenex SE (NASDAQ:ARGX) by 14.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 108,509 shares of the company’s stock after selling 19,021 shares during the quarter. argenex accounts for about 1.4% of TimesSquare Capital Management LLC’s investment portfolio, making the stock its 16th largest position. TimesSquare Capital Management LLC’s holdings in argenex were worth $91,251,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. grew its holdings in argenex by 2.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after buying an additional 12 shares during the last quarter. Valeo Financial Advisors LLC grew its holdings in argenex by 0.9% in the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after buying an additional 12 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its holdings in argenex by 3.4% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after buying an additional 13 shares during the last quarter. Allworth Financial LP grew its holdings in argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after buying an additional 13 shares during the last quarter. Finally, Portside Wealth Group LLC grew its holdings in argenex by 2.8% in the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after buying an additional 16 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Trading Down 2.9%

Shares of NASDAQ:ARGX opened at $776.26 on Tuesday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a market capitalization of $48.03 billion, a PE ratio of 34.56, a PEG ratio of 1.28 and a beta of 0.46. The business’s 50 day moving average is $761.26 and its 200-day moving average is $816.23.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, sell-side analysts predict that argenex SE will post 25.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARGX. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Guggenheim lifted their price objective on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Wells Fargo & Company lifted their price objective on argenex from $1,247.00 to $1,260.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.